Free Trial
NASDAQ:CLOV

Clover Health Investments (CLOV) Stock Price, News & Analysis

Clover Health Investments logo
$2.58 -0.02 (-0.58%)
Closing price 07/3/2025 03:58 PM Eastern
Extended Trading
$2.58 0.00 (0.00%)
As of 07/3/2025 04:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Clover Health Investments Stock (NASDAQ:CLOV)

Key Stats

Today's Range
$2.54
$2.64
50-Day Range
$2.58
$3.76
52-Week Range
$1.24
$4.87
Volume
4.32 million shs
Average Volume
7.04 million shs
Market Capitalization
$1.31 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.83
Consensus Rating
Moderate Buy

Company Overview

Clover Health Investments Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
45th Percentile Overall Score

CLOV MarketRank™: 

Clover Health Investments scored higher than 45% of companies evaluated by MarketBeat, and ranked 1834th out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Clover Health Investments has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Clover Health Investments has received no research coverage in the past 90 days.

  • Read more about Clover Health Investments' stock forecast and price target.
  • Earnings Growth

    Earnings for Clover Health Investments are expected to grow in the coming year, from ($0.12) to ($0.07) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Clover Health Investments is -51.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Clover Health Investments is -51.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Clover Health Investments has a P/B Ratio of 3.79. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Clover Health Investments' valuation and earnings.
  • Percentage of Shares Shorted

    5.77% of the float of Clover Health Investments has been sold short.
  • Short Interest Ratio / Days to Cover

    Clover Health Investments has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Clover Health Investments has recently increased by 9.00%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Clover Health Investments does not currently pay a dividend.

  • Dividend Growth

    Clover Health Investments does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    5.77% of the float of Clover Health Investments has been sold short.
  • Short Interest Ratio / Days to Cover

    Clover Health Investments has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Clover Health Investments has recently increased by 9.00%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Clover Health Investments has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Clover Health Investments this week, compared to 5 articles on an average week.
  • Search Interest

    Only 4 people have searched for CLOV on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.
  • MarketBeat Follows

    5 people have added Clover Health Investments to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Clover Health Investments insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    24.07% of the stock of Clover Health Investments is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 19.77% of the stock of Clover Health Investments is held by institutions.

  • Read more about Clover Health Investments' insider trading history.
Receive CLOV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Clover Health Investments and its competitors with MarketBeat's FREE daily newsletter.

CLOV Stock News Headlines

Clover Health Set to Join Russell 3000® Index - Morningstar
Clover Health Set to Join Russell 3000® Index
The End of Elon Musk…?
The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.
3 Reasons to Sell CLOV and 1 Stock to Buy Instead
See More Headlines

CLOV Stock Analysis - Frequently Asked Questions

Clover Health Investments' stock was trading at $3.15 at the beginning of the year. Since then, CLOV shares have decreased by 18.3% and is now trading at $2.5750.

Clover Health Investments, Corp. (NASDAQ:CLOV) released its quarterly earnings results on Tuesday, May, 6th. The company reported $0.05 earnings per share for the quarter, beating analysts' consensus estimates of ($0.07) by $0.12. The firm earned $462.33 million during the quarter, compared to analysts' expectations of $466.93 million. Clover Health Investments had a negative net margin of 1.69% and a negative trailing twelve-month return on equity of 7.42%.
Read the conference call transcript
.

Shares of CLOV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Clover Health Investments investors own include Zomedica (ZOM), AMC Entertainment (AMC), SoFi Technologies (SOFI), Jumia Technologies (JMIA), NIO (NIO), Meta Platforms (META) and NVIDIA (NVDA).

Company Calendar

Last Earnings
5/06/2025
Today
7/04/2025
Next Earnings (Estimated)
8/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MEDICAL INFO SYS
Sub-Industry
Insurance
Current Symbol
NASDAQ:CLOV
Fax
N/A
Employees
680
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.83
High Stock Price Target
$6.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+87.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$43.01 million
Pretax Margin
-1.64%

Debt

Sales & Book Value

Annual Sales
$1.37 billion
Price / Cash Flow
N/A
Book Value
$0.68 per share
Price / Book
3.79

Miscellaneous

Free Float
386,421,000
Market Cap
$1.31 billion
Optionable
Optionable
Beta
1.86
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:CLOV) was last updated on 7/4/2025 by MarketBeat.com Staff
From Our Partners